Spectrum Pharmaceuticals

Events and Presentations

DAY HI:

DAY LOW:

VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events and Presentations

Date	Title	Format
Sep 10, 2022	ESMO Congress 2022: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC)	ESMO Congress 2022: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC) 813.3 KB
May 26, 2022	ASCO 2022: Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib	ASCO 2022: Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib 685.6 KB
Apr 12, 2022	AACR 2022: Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations	AACR 2022: Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations 492.4 KB
Mar 07, 2022	ESMO TAT Virtual Congress 2022: Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4	ESMO TAT Virtual Congress 2022: Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4 1.1 MB
Oct 07, 2021	AACR-NCI-EORTC – Virtual International Conference: Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers	AACR-NCI-EORTC – Virtual International Conference: Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers 1.5 MB
Sep 18, 2021	ESMO Congress 2021: Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)	ESMO Congress 2021: Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4) 474.8 KB
Jun 04, 2021	2021 ASCO Annual Meeting: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations	2021 ASCO Annual Meeting: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations 536.3 KB
Apr 10, 2021	Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations	Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations 515.2 KB
Mar 05, 2021	38th Annual Miami Breast Cancer Conference: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)	38th Annual Miami Breast Cancer Conference: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC) 753.2 KB
Mar 02, 2021	ESMO TAT Virtual Congress 2021: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer	ESMO TAT Virtual Congress 2021: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer 206.1 KB

Date	Title
Nov 10, 2022 4:30 PM EST	Spectrum Pharmaceuticals 3Q 2022 Earnings Call View Webcast
Aug 11, 2022 8:30 AM EDT	Spectrum Pharmaceuticals 2Q 2022 Earnings Call View Webcast
Jun 16, 2022 9:00 AM EDT	JMP Securities Life Sciences Conference View Webcast
Jun 9, 2022 1:00 PM EDT	Jefferies Healthcare Conference View Webcast
May 24, 2022 7:00 AM EDT	H.C. Wainwright Global Investment Conference View Webcast
May 12, 2022 4:30 PM EDT	Spectrum Pharmaceuticals 1Q 2022 Earnings Call View Webcast
Mar 17, 2022 4:30 PM EDT	Spectrum Pharmaceuticals 4Q 2021 Earnings Call View Webcast